Instruction 1(b)

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burde	en								
hours per response:	0.5								

1. Name and Address of Reporting Person* ULLIAN ELAINE (Last) (First) (Middle)			2. Issuer Name and Ticker or Trading Symbol <u>VERTEX PHARMACEUTICALS INC /</u> <u>MA</u> [VRTX]		tionship of Reporting Perso all applicable) Director Officer (give title below)	n(s) to Issuer 10% Owner Other (specify below)
C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET (Street)		· · · ·	3. Date of Earliest Transaction (Month/Day/Year) 11/15/2005			
			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indiv Line) X	,	
CAMBRIDGE	MA	02139			Form filed by More than (Person	0
(City)	(State)	(Zip)				

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code 8)				5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership		
			Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(Instr. 4)	
Common Stock	11/15/2005		М		10,000	Α	\$10.05	10,600	D		
Common Stock	11/15/2005		S		10,000	D	\$26.27	600	D		
Common Stock	11/15/2005		М		7,500	A	\$9.09	8,100	D		
Common Stock	11/15/2005		S		7,500	D	\$26.3	600	D		
Common Stock	11/15/2005		М		37,500	A	\$11.62	41,000	D		
Common Stock	11/15/2005		S		37,500	D	\$26.27	600	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option	\$10.05	11/15/2005		A			10,000	06/01/1999 ⁽¹⁾	05/31/2009	Common Stock	10,000	\$ <mark>0</mark>	100,000	D	
Stock Option	\$9.09	11/15/2005		A			7,500	06/01/2004 ⁽¹⁾	05/31/2014	Common Stock	7,500	\$ <mark>0</mark>	925,000	D	
Stock Option	\$11.62	11/15/2005		A			37,500	12/12/1997 ⁽²⁾	12/11/2007	Common Stock	37,500	\$26.27	55,000	D	

Explanation of Responses:

1. Right to buy under 1996 Stock and Option Plan. Fully vested on grant date.

2. Right to buy under 1996 Stock and Option Plan, vesting in equal quarterly installment over four years from 12/12/1997.

Remarks:

Kenneth S. Boger, Attorney-In-11/18/2005

** Signature of Reporting Person Date

Fact

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.